Lilly bets on in vivo CAR-T with $2.4B Orna Therapeutics deal
TL;DR Summary
Eli Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion to gain an in vivo CAR-T platform using engineered circular RNA delivered by lipid nanoparticles, led by ORN-252 targeting CD19 for autoimmune diseases; terms include upfront and milestone-based payments. The deal follows a wave of pharma acquisitions in this space as Lilly expands its genetic medicines pipeline and Orna has drawn funding and collaborations since its 2021 launch.
- Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena Fierce Biotech
- Eli Lilly to buy Watertown biotech Orna Therapeutics for $2.4 billion The Boston Globe
- Lilly to acquire Orna Therapeutics to advance cell therapies Eli Lilly
- Lilly bets on next-generation cell therapy with $2.4 billion deal for Orna Reuters
- Lilly Strikes Deal for Biotech Orna Worth Up to $2.4 Billion Bloomberg.com
Reading Insights
Total Reads
1
Unique Readers
9
Time Saved
3 min
vs 4 min read
Condensed
89%
612 → 70 words
Want the full story? Read the original article
Read on Fierce Biotech